Collegium Pharmaceutical Inc (COLL)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 59.76% | 57.55% | 45.15% | 54.40% | 58.01% |
| Operating profit margin | 26.91% | 29.46% | -22.54% | -16.87% | -1.64% |
| Pretax margin | 15.61% | 13.36% | -6.22% | -1.22% | 8.90% |
| Net profit margin | 10.96% | 8.50% | -5.39% | 25.83% | 8.63% |
Collegium Pharmaceutical Inc's profitability ratios show fluctuations over the years. The gross profit margin has decreased from 58.01% in 2020 to 45.15% in 2022, but then rose to 59.76% in 2024, indicating volatility in the company's ability to generate profit from its core operations.
The operating profit margin was negative in 2020 and 2021, improving significantly to 29.46% in 2023 and 26.91% in 2024. This suggests that Collegium Pharmaceutical has been able to control its operating expenses more effectively in recent years, leading to better operational profitability.
The pretax margin was positive in 2020, turned negative in 2021 and 2022, then rebounded to 15.61% in 2024. This indicates variations in the company's ability to generate profit before taxes, which may be influenced by factors such as changes in revenue and expenses.
The net profit margin also showed variability, with a significant increase from 2020 to 2021, followed by a decline in 2022, and subsequent improvements in 2023 and 2024. This suggests that Collegium Pharmaceutical's profitability after accounting for all expenses and taxes has been fluctuating, potentially due to changes in revenue or cost structure.
Overall, Collegium Pharmaceutical's profitability ratios demonstrate mixed performance, with improvements in some areas over the years but also periods of decline or instability. It will be important for the company to continue monitoring and managing its profitability metrics to ensure sustainable long-term financial health.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 10.21% | 14.60% | -8.91% | -6.75% | -0.79% |
| Return on assets (ROA) | 4.16% | 4.21% | -2.13% | 10.33% | 4.16% |
| Return on total capital | 75.40% | 81.40% | 17.64% | 8.69% | 30.35% |
| Return on equity (ROE) | 30.23% | 24.64% | -12.83% | 35.24% | 14.38% |
The profitability ratios of Collegium Pharmaceutical Inc show varying performance over the years.
1. Operating return on assets (Operating ROA) fluctuated significantly, starting at -0.79% in December 2020, declining to -6.75% in December 2021, further decreasing to -8.91% in December 2022, then experiencing a notable improvement to 14.60% in December 2023, and finally settling at 10.21% in December 2024.
2. Return on assets (ROA) had a mixed performance, starting at 4.16% in December 2020, improving to 10.33% in December 2021, dropping to -2.13% in December 2022, slightly recovering to 4.21% in December 2023, and stabilizing at 4.16% in December 2024.
3. Return on total capital showed fluctuations, with a high of 81.40% in December 2023, a significant decrease from 30.35% in December 2020 to 8.69% in December 2021, followed by an increase to 17.64% in December 2022, and a relatively stable 75.40% in December 2024.
4. Return on equity (ROE) performance also varied, starting at 14.38% in December 2020, rising sharply to 35.24% in December 2021, turning negative to -12.83% in December 2022, rebounding to 24.64% in December 2023, and closing at 30.23% in December 2024.
Overall, Collegium Pharmaceutical Inc's profitability ratios demonstrate fluctuations and mixed performance over the period, indicating the company's varying ability to generate profits from its assets and equity. It is essential for stakeholders to closely monitor these ratios to assess the company's financial health and performance effectively.